key: cord-0987734-71k4huh4
authors: Dzutseva, V.; Lioznov, D.; Amosova, I.; Sheetikov, S. A.; Zornikova, K. V.; Serdyuk, Y.; Efimov, G. A.; Tsyferov, M.; Khmelevskii, M.; Afansiev, A.; Khomyakova, N.; Zubkov, D.; Tikhonov, A.; Zhu, T.; Barreto, L.
title: Immunogenicity and safety of a recombinant adenovirus type-5 COVID 19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia
date: 2022-03-11
journal: nan
DOI: 10.1101/2022.03.01.22271507
sha: 09347f6e8cfbc42d05df844b4ab76eab375fdbc6
doc_id: 987734
cord_uid: 71k4huh4

ABSTRACT Background: To determine the immunogenicity, efficacy, reactogenicity, and safety of a single dose of recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV, 5 x 1010 viral particles per 0.5 mL dose), we conducted a single-dose, randomised, double-blind, placebo-controlled, parallel group (3:1 Ad5 nCoV:placebo), phase 3 trial (Prometheus). Methods: From 11-September-2020 to 05-May-2021, across six sites in the Russian Federation, 496 participants were injected with either placebo or Ad5-nCoV expressing the full-length spike (S) protein from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Results: Seroconversion (the primary endpoint) rates of 78.5% (95% CI: 73.9; 82.6) against receptor binding domain (RBD), 90.6% (95% CI: 87.2; 93.4) against S protein and 59% (95% CI: 53.3; 64.6) against neutralising SARS-CoV2 antibodies 28 days post-vaccination. Geometric mean titres (GMTs) were also elevated for antibodies against the RBD (405.32 [95% CI: 361.58; 454.46]) and S protein (678.86 [95% CI: 607.44; 754.40]) compared to the GMT of neutralising antibodies against SARS-CoV-2 (16.73 [95% CI: 15.36; 18.22]). Using an IFN-{gamma}ELISpot assay after stimulating the cells with full-length S protein we showed that the Ad5-nCoV vaccine induced the most robust cellular immune response on Days 14 and 28. Up to Day 28, the primary and all secondary endpoints of the Ad5-nCoV vaccine were statistically superior to the placebo (p<0.001). Systemic reactions were reported in 113 of 496 (22.8%) participants (Ad5-nCoV, 26.9%; Placebo, 10.5%), and local reactions were reported in 108 (21.8%) participants (Ad5-nCoV, 28.5%; Placebo, 1.6%). These were generally mild and resolved within 7 days after vaccination. Of the six serious adverse events reported, none of the events were vaccine related. There were no deaths or premature withdrawals. Conclusion: A single-dose of Ad5-nCoV vaccine induced a marked specific humoral and cellular immune response with a favourable safety profile. Trial Registration: ClinicalTrials.gov: NCT04540419

Trial Registration: ClinicalTrials.gov: NCT04540419 43 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. added to the wells, and plates were incubated for 1 h at 37±0.5°C in a humidified incubator. Medium 156 was removed from wells, replaced with a mixture of the most highly diluted (1:1280) serum and 157 virus, and plates were incubated at 37±0.5°C and 5% CO 2 for 4 days. Anti-adenovirus neutralising 158 antibodies were also determined using microneutralisation assay; A549 cell monolayers were 159 incubated in 96-well plates with serial dilutions (1:10 to 1:1280) of participant serum and working 160 dilutions of Ad5 (Adenovir; Smorodintsev Research Institute of Influenza). Plates were incubated for 161 2 h at 36±0.5°C and 5% CO 2 . Medium was removed from wells, replaced with a mixture of diluted 162 serums and working virus dilution, and plates were incubated at 36±0.5°C and 5% CO 2 for 72 h. For 163 both microneutralisation assays, results were assessed by visual inspection of cytopathic effects. 164

Serum titres were determined as the maximum dilution at which complete inhibition of viral 165 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 11, 2022. ; https://doi.org/10.1101/2022.03.01.22271507 doi: medRxiv preprint reproduction was detected as the result of interaction between virus and specific antibodies; the 166 detection limit was 1:10. Antibody titres undetectable in serum were assigned values of half of the 167 detection limits for calculation. 168

Sequence encoding Δ Furin variant of SARS-CoV-2 S protein (amino acids 1-1213) containing a C-169

terminal Gly-Gly-6xHis tag was subcloned into the pMCAG-2T vector using the GeneArt Type IIs 170

Assembly Kit, BbsI (Thermo Fisher Scientific), according to the manufacturer's instructions. 171

Recombinant SARS-CoV-2 S protein was expressed in Expi293F cells (Thermo Fisher Scientific) as 172 previously described [16] . Five days following transfection, cells were harvested via centrifugation 173 (15,600 x g), the supernatant was concentrated and diafiltered using the ÄKTATM flux tangential 174 flow filtration system (Cytiva) into buffer A (10 mM phosphate buffer, 2.7 mM KCl, 500 mM NaCl, 175 pH 8.0). The His-tagged S protein was further purified using Ni-NTA agarose resin (Qiagen), 176 washed with buffer A containing 30 mM imidazole and eluted in buffer A with 200 mM imidazole. 177

Using a Slide-A-Lyzer Dialysis Cassette (20K MWCO, Thermo Fisher Scientific), the eluate was 178 dialysed against PBS (10 mM phosphate buffer, 2.7 mM KCl, 137 mM NaCl, pH 7.5) before use in 179 subsequent experiments. 180

To measure the cellular immune response from T cells (specifically CD8 + and CD4 + T cells), 181 peripheral blood mononuclear cells (PBMCs) from participants were isolated and tested as described 182

by Shomuradova et al. [16] . In brief, 30 mL of venous blood was collected from the participants and 183 centrifuged via a density gradient (Ficoll; PanEco) for 400 x g for 30 min to isolate PBMCs, which 184 were washed with PBS containing 2 mM EDTA. For the enzyme-linked immunospot (ELISpot) 185 assay, PBMCs (3 x 10 5 cell/well) were plated into 96-well nitrocellulose plate that was pre-coated 186 with human IFN-γ capture antibody (ImmunoSpot kit Human IFNγ Single-Color ELISpot kit, 187 Cellular Technology Limited) in serum-free test medium (Cellular Technology Limited) containing 1 188 mM GlutaMAX (Gibco) in a final volume of 200 µL/well as previously described [16] . To stimulate 189 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. received telephone calls after 2, 3, 4 and 5 months, and were asked to answer questions to assess 209 safety and determine if they presented with signs of an acute respiratory infection due to Haematology, clinical biochemistry, coagulation testing and urinalysis were conducted at screening, 211 day 2 and Day 28; electrocardiography was performed at screening and on day 2. Immunoglobulin E 212 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Of note, two definitions were used to define seroconversion, one quantitative and one qualitative. 230

The primary and secondary endpoints used the quantitative definition: the proportion of participants 231 with at least a 4-fold increase in antibody titres against SARS-CoV-2 S protein and/or its RBD, 232 specifically. The qualitative analysis was defined as an antibody titre above the lower limit of 233 quantification (LLOQ) post-vaccination (if the baseline titre was below the LLOQ), or a 4-fold 234 increase over baseline post-vaccination (if the baseline titre was above the LLOQ). 235 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. of the interim analysis and to ensure 90% power for the between-group comparison of the primary 238 variable, 180 subjects were to be included. This was based on the assumptions of a 20% 239 seroconversion rate in the Placebo group (based on quantitative analysis), superiority of the vaccine 240 group of ≥ 30% (conservative assumption, odds ratio = 4), corrected two-sided significance level of 241 0.02616 (one-sided level of 0.01308) and the randomisation ratio of 3:1. Considering potential 242 dropouts from the study during the initial observation period of 28 days (10% of subjects), the total 243 number of randomised participants was increased to 200. To provide more detailed safety and 244 efficacy data (including age subgroups) and to descriptively present the frequency of confirmed 245 COVID-19 cases that occurred within 6 months post-vaccination (except for COVID-19 cases that 246 developed during the first 14 days after the vaccination), a sample size of 500 was selected. 247

An unblinded interim analysis was originally planned and conducted in this clinical trial when 248 obtaining partial information to evaluate the primary endpoint, gathered from the first 200 249 randomised volunteers and based on the results collected up to Day 28 (Visit 5), including the data 250 for those who left the trial before Visit 5. Subsequently, an alpha spending function (that is, an 251 increasing function of the proportion of the maximum sample size) of the Pocock type was employed 252 to adjust the level of significance due to the multiple comparisons of the primary variable in the 253 planned interim and final analysis sets. Analyses were performed with bilateral alpha levels of 254 0.02616 and 0.03039 on the interim and final analysis sets, respectively (with a total bilateral 255 significance level of 5%). 256

Variables representing the seroconversion rate (the proportion of participants with at least a 4-fold 257 increase in antibody titres) were tabulated by evaluation time-points and treatment groups, and two-258 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. presented. Cellular immunity results were analysed in participants from the FAS that provided at 281 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 11, 2022. ; https://doi.org/10.1101/2022.03.01.22271507 doi: medRxiv preprint 15 least one cellular immunity assessment result. Prophylactic efficacy results are presented for the PPS 282 (for efficacy analysis). The safety analysis set included all randomized volunteers who received a 283 dose of the vaccine. 284

Participants were not directly involved in the development, implementation, or interpretation of this 286 study due to the requirement for a quick response to the rapidly-evolving coronavirus pandemic. 287

The Authors commit to making the relevant anonymised participant level data available upon 289 reasonable request for 3 years following publication of this study. Requests should be directed to the 290 corresponding author. 291 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Out of the 783 participants who were screened, this analysis included 500 eligible participants 293 intended for vaccination at six locations in the Russian Federation between 11 September 2020 and 294 11 November 2020. Of these, 374 participants were randomised to the Ad5-nCoV group and 126 to 295 the Placebo group (Fig. 1) . The safety analysis set included 496 participants, the FAS for 296 immunogenicity analysis included 495 participants, and the PPS for efficacy analysis included 481 297 participants. 298 The mean age of participants was 41.2 years (range 18-79 years), with 300 (60.5%) participants aged 300 18-44 years, 161 (32.5%) aged 45-59 years, and 35 (7.1%) aged 60 years or older (Table 1) . There 301 were more males (297 out of 496 [59.9%]) than females. The vast majority of the participants 302 (99.4%) were white race and 3 participants were Asian. Baseline characteristics were largely similar 303 across groups. 304 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Baseline antibody titres of the participants in the FAS (Ad5-nCoV; placebo) were similar for anti-307 RBD antibodies (50.1; 50.0), anti-S protein (50.3; 50.3), neutralising anti-SARS-CoV-2 antibodies 308 (5.0; 5.0), as well as neutralising antibodies against the Ad5 vector (11.3; 8.8). Administration of the 309 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Pearson's correlation coefficients between baseline GMTs to Ad5, GMTs to RBD and S protein 393 antibodies as well as neutralising SARS-CoV-2 antibodies were calculated. There was a negative 394 correlation of -0.36 between baseline GMT to Ad5 and GMT to RBD on Day 14 that weakened 395 to -0.05 at 6 months post-vaccination. The correlations between baseline GMT and GMTs to S 396 protein and neutralising SARS-CoV-2 antibodies decreased by Month 6 (Fig. 6) . The decrease in 397 correlation was less pronounced between GMTs to RBD, indicating that the relationship between 398 levels of baseline Ad5 GMTs to the COVID-19 humoral immune response weakens over time 399 following vaccination. 400 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. vaccine (Ad5-nCoV: 34.9%; Placebo: 20.2%). The majority of vaccine-related AEs were reported 493 during the first 7 days after vaccination (Ad5-nCoV: 33.1%; Placebo: 20.2%). In both groups, the 494 most common AEs were out-of-range laboratory measurements: 34.4% reported by participants in 495 the Ad5-nCoV group and 16.9% from the Placebo group. The most pronounced differences in AE 496 incidence in the Ad5-nCoV group compared with the Placebo group were: increases in C-reactive 497 protein (17.6% vs. 2.4%), monocytes (4.0% vs. 0%) and aspartate aminotransferase (1.6% vs. 1.6%) 498 as well as a decrease in neutrophils (6.2% vs 2.4%) (S6 Table) . 499

For most participants, AEs were mild, reported in 28.5% of the Ad5-nCoV group and 16.1% of the 500 Placebo group. Moderate events were registered in 5.6% of participants who received the Ad5-nCoV 501 vaccine and 4.0% who received the placebo. By comparison, SAEs occurred in 0.8% of participants 502 in the Ad5-nCoV group, but none in the Placebo group; these included increases in C-reactive 503 protein (0.5%) and blood fibrinogen levels (0.5%). 504

For most participants, general and injection site reactions and AEs resolved within 7 days after 505 vaccination. 506

Results of the analysis of laboratory parameters demonstrated a trend towards an increase in C-507 reactive protein levels, an increase in the red cell sedimentation rate, an increase in the mean 508 percentage of monocytes, and a decrease in the mean percentage of neutrophils after administration 509 of Ad5-nCoV. The changes in the examined laboratory parameters were pronounced the day after 510 vaccination, but had largely resolved by Day 28. 511

The proportion of participants in the Ad5-nCoV group with elevated IgE at Day 28 showed no 512 changes from screening: 73/372 (19.6%) to 76/365 (20.8%). 513 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial including 500 adult 515 participants aged 18-85 years (mean age: 41.2 years), the immunogenicity, efficacy and safety of the 516 Ad5-nCoV COVID-19 vaccine was assessed up to 6 months after vaccination. Both study groups 517 We theorized two possible explanations. First, some individuals might have been asymptomatic 530 while infected with COVID-19, or COVID-19-positive patients did not report their symptoms to the 531 study's physicians. Second, individuals in the Placebo group might have taken a commercially 532 available antibody test that was widely available in Russia and decided to receive another 533 vaccination after observing their low antibody titres, thereby confounding their treatment status. Two 534 participants were excluded from the PPS for this reason, but many more could have been unreported. 535 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Russian participants, those with baseline levels of anti-Ad5 antibodies showed a very small group of 547 7 (1.4%) participants with titres of approximately 1:320 (Fig. 4) . All of them were in the subgroup of 548 participants aged 18 to 45 years. 549

In this study, we uncovered the response of pre-existing immunity to Ad5 and showed how it affects 550 subsequent humoral immune responses as well as the longevity of immunity to COVID-19. In 551 participants vaccinated with Ad5-nCoV, there was no difference in humoral immunity to COVID-19 552 between those with baseline Ad5 titres above or below the cut-off of 1:200. However using a cut-off 553 of 1:5, we showed that those with baseline Ad5 titres of 1:5 displayed a greater amount of GMTs to 554 anti-RBD and S protein antibodies as well as neutralising SARS-CoV-2 antibodies than those with a 555 higher baseline ratio of Ad5 titres (Fig. 5) . The relationship between the levels of baseline Ad5 556

GMTs to the respective antigen tends to weaken over time following vaccination (Fig. 6 ). Studies 557 with longer follow-up periods would help to clarify the longevity of the immune response in those 558 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 11, 2022. ; https://doi.org/10.1101/2022.03.01.22271507 doi: medRxiv preprint vaccinated with Ad5-nCoV. Moreover, studies with a larger dataset would help to determine if pre-559 existing immunity to Ad5 correlates to protection efficacy. 560

Our study provides data on the incidence of anti-Ad5 immunity in the Russian population, admittedly 561

in a relatively small sample size. Almost all participants had pre-existing neutralising antibodies to 562

Ad5, although levels were generally very low. No such data were available before this study, and 563 only limited and highly variable data are available for the level of Ad5 immunity in Europe. 564

The results from this study demonstrate that the experimental Ad5-nCoV vaccine has a good safety 565 profile comparable with the findings of preceding clinical trials in healthy adults. Most post-566 vaccination AEs were mild or moderate in severity. Although the proportions of participants who 567 reported adverse reactions such as an increase in body temperature, headache, and pain at the 568 injection site were higher in those that received the Ad5-nCoV vaccine, adverse reactions within 569 28 days were generally mild to moderate and the majority resolved within 7 days after vaccination. 570

All Grade 3 AEs occurred among participants from the Ad5-nCoV group and were similar to 571 commonly reported AEs after other types of immunisation. 572

There are currently multiple recombinant Ad-vectored COVID-19 candidate vaccines in 573 development [4-7, 9, 10, 20, 21] . The most relevant comparator vaccine in terms of the practicalities 574 of storage, transport and administration is the Ad26.COV2.S vaccine [22] . Like the Ad5-nCoV 575 vaccine, it can be administered as a single dose, stored in a standard refrigerator without the need for 576 ultra-low temperature freezing and is stable at room temperature prior to administration. An interim 577 analysis of Ad26.COV2.S showed that vaccine-induced neutralising antibodies against wild-type 578 virus were detected in 95% or more of participants on day 29 after dosing. Our qualitative analysis 579 used a similar definition of seroconversion to that used to assess the Ad26.COV2.S vaccine [22] ; as 580 well as including participants who seroconverted from below the LLOQ of the assay at baseline to 581 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 11, 2022. ; https://doi.org/10.1101/2022.03.01.22271507 doi: medRxiv preprint detectable antibodies at Day 28, it included those with a 4-fold or greater increase in antibody titre 582 over the same period. The Ad5-nCoV vaccine provided a similar antibody response to 583

Ad26.COV2.S: 95.9% of subjects developed antibodies to the S protein and 92.5% to the smaller 584 anti-RBD region by Day 28. 585

This study has several limitations. First, the participants included in this study were all white, 586 although conversely, this also provided the first data in a non-Chinese, European population. Second, 587 this trial did not include children or pregnant women, and there were only a small number of older 588 adults (35 were ≥ 60 years in the Ad5-nCoV group). An ideal candidate vaccine for COVID-19 589 should cover vulnerable populations of all ages. Anti-S protein-specific antibodies have been 590 reported to decline rapidly in individuals who have recovered from COVID-19, especially those who 591 were asymptomatic or had mild symptoms [23] . Third, the sample size was relatively small and some 592 of the calculated 95% CIs were wide. Finally, virus mutation, an emerging problem, may reduce the 593 effectiveness of current vaccines [24]. It is not known whether participants of this study were 594 exposed to any COVID-19 variants. Further study is underway to determine neutralising antibodies 595 to the widely circulating variants following vaccination with Ad5-nCoV, which include but are not 596 limited to the Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) variants. 597

Analysis of data from this phase 3 trial demonstrated the immunogenicity and safety of this Ad5-599 vector based COVID-19 vaccine. More data are required to determine whether this vaccine reduces 600 infections and transmission. Overall, this stable, single-dose vaccine could contribute to the global 601 fight against the evolving SARS-CoV-2 virus. 602 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Dr Antria Siakalli and Dr Caitlin Tolbert 605 of Niche Science and Technology Ltd

Supporting Information 608 S1 Protocol. Study Protocol

Systemic (general) post-vaccination reactions (Safety population)

Systemic (general) post-vaccination reactions by severity (Safety population)

Summary of all severe adverse events that led to hospitalisation or prolonged 613 hospitalisation

Local post-vaccination reactions (Safety population)

Local post-vaccination reactions by severity (Safety population)

Other adverse events unrelated to vaccination reactions (Safety population)

Author Contributions

The Spanish Influenza Pandemic: a 655 lesson from history 100 years after 1918

Quarantine alone or in combination with other public health measures to control COVID-19: a rapid 659 review

Safety and 661 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and 664 efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of 665 four randomised controlled trials in Brazil, South Africa, and the UK

Efficacy and Safety 668 of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous 672 prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies 673 from Russia

COVID-19 Vaccine: A comprehensive status report

Potent neutralization of 677 severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks 678 receptor association

Immunogenicity and safety of a 680 recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: 681 a randomised, double-blind, placebo-controlled, phase 2 trial

Safety, tolerability, and 684 immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, 685 open-label, non-randomised, first-in-human trial

Food and Drug Administration (FDA)

Development and Licensure of Vaccines to Prevent COVID-19

Rules for Conducting Studies of Biological Medicinal Products of the Eurasian Economic

Union

Clinical Trial of Recombinant Novel Coronavirus Vaccine

Type 5 Vector) Against COVID-19

SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human

Seroprevalence of neutralizing 706 antibodies to human adenovirus type 5 in healthy adults in China

International 712 seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

Covid: what do we know about China's coronavirus vaccines?

Sputnik V COVID-19 vaccine candidate appears safe and effective

Clinical and immunological 722 assessment of asymptomatic SARS-CoV-2 infections

Oxford/AstraZeneca jab fails to 725 prevent mild and moderate Covid from S African strain, study shows. Financial Times

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

The most commonly reported reactions in the Ad5-nCoV group included increase in body 464 temperature (20.2%), headache (5.9%), fatigue (5.4%), myalgia (4.8%) and arthralgia (1.9%; S1 465 Table) . For most participants, general immunisation reactions were mild (Grade 1, 21.0%). Moderate 466 (Grade 2) reactions occurred in 4.6% of participants and included increase in body temperature, 467 headache, myalgia, arthralgia, and fatigue. Severe (Grade 3) reactions, including an increase in body 468 temperature (39.0-40.0 °C), occurred in 4 participants, and myalgia occurred in only 1 participant 469 (Table 2 and S2 Table) . 470 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In the Placebo group, reactions included increase in body temperature (6.5%), headache (4.8%), 471 fatigue (5.4%) and diarrhoea (0.8%). These AEs were mild or moderate; no severe reactions were 472 reported ( Table 2, S1 Table and S2 Table) . 473There were no fatal outcomes. During the first 7 days after vaccination, a total of six serious AEs 474 (SAEs) were reported (Table 2) : one SAE in 1 (0.3%) participant from the Ad5-nCoV group and five 475 SAEs in 5 (4.0%) participants from the Placebo group. Of note, two of the participants from the 476 Placebo group were hospitalised due to COVID-19. For the only SAE event experienced by a 477 participant from the Ad5-nCoV group, the event was found to have no connection with the study 478 drug. The SAEs are described in S3 Table. 479

Injection site reactions occurred in 106 participants (28.5%) who received the Ad5-nCoV vaccine. 481By comparison, only 2 participants in the Placebo group (1.6%) experienced an injection site 482 reaction including swelling and pain or induration (S4 Table) , all of which were Grade 1 in severity 483 (S5 Table) . The most common reactions included pain (16.9%), erythema (14.8%) and induration at 484 the injection site (4.8%) (S4 Table) . As listed in S5 Table, Table 2 , these AEs were assessed by the investigators as related to the 492 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 11, 2022. ; https://doi.org/10.1101/2022.03.01.22271507 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The authors confirm that the data supporting the findings of this study are available within the article. 649

The corresponding author and guarantor (Vitalina Dzutseva) affirms that this manuscript is an 651 honest, accurate, and transparent account of the study being reported; that no important aspects of the 652 study have been omitted; and that any discrepancies from the study as planned have been explained. 653 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 11, 2022. ; https://doi.org/10.1101/2022.03.01.22271507 doi: medRxiv preprint 35 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 11, 2022. ; https://doi.org/10.1101/2022.03.01.22271507 doi: medRxiv preprint 36 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 11, 2022. ; https://doi.org/10.1101/2022.03.01.22271507 doi: medRxiv preprint 37 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.